Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
41
Recruiting, any sponsor type, condition "herpes"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed334
41 trials
Showing 1 to 25, recently updated first.
University of Sao Paulo General HospitalAcademic, hospital or other
NCT07341386 · 62 participants (planned) · Start Jun 25, 2026 · Primary completion Dec 20, 2027
Drug: Acyclovir (ACV) · For: Autoimmune Rheumatic Diseases; Recurrent Herpes Simplex; Prevention
Sites: São Paulo, Brazil
National Cancer Institute (NCI)NIH
NCT07308886 · 55 participants (planned) · Start Apr 8, 2026 · Primary completion Jan 31, 2036
Drug: CYT107 · For: Kaposi Sarcoma
Sites: Bethesda, Maryland
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03911388 · 24 participants (planned) · Start Sep 12, 2019 · Primary completion Dec 31, 2027
Drug: G207 · For: Neoplasms, Brain; Glioblastoma Multiforme; Glioblastoma of Cerebellum and 30 more
Sites: Birmingham, Alabama; St Louis, Missouri; Houston, Texas
- Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)Pivotal-lookingRecruiting
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT07920172 · 500 participants (planned) · Start Nov 10, 2026 · Primary completion May 23, 2029
Drug: Low-dose adjuvanted recombinant zoster vaccine; High-dose adjuvanted recombinant zoster vaccine (0 and 30 days schedule) and 4 more · For: Herpes Zoster
Sites: Guangxi, China · 2 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05580458 · 225 participants (planned) · Start Mar 13, 2023 · Primary completion Feb 1, 2027
Drug: Shingrix · For: Herpes Zoster
Sites: Bethesda, Maryland
- Safety of the Herpes Zoster Subunit Vaccine in LupusPivotal-lookingRecruiting
NYU Langone HealthAcademic, hospital or other
NCT05559671 · 224 participants (planned) · Start Dec 21, 2023 · Primary completion Feb 1, 2028
Drug: Herpes Zoster Subunit (HZ/su) Vaccine; Placebo · For: Systemic Lupus Erythematosus
Sites: New York, New York; Oklahoma City, Oklahoma
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07076498 · 20 participants (planned) · Start Apr 23, 2026 · Primary completion Dec 31, 2029
Drug: M032 · For: Glioma
Sites: Houston, Texas
- Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AbovePivotal-lookingRecruiting
Suzhou Abogen Biosciences Co., Ltd.Industry
NCT07817108 · 18,000 participants (planned) · Start Jun 27, 2026 · Primary completion Oct 17, 2027
Drug: ABO1108; Placebo · For: Varicella-zoster Virus
Sites: Jinan, China; Nanning, China; Shijiazhuang, China · 4 sites in all
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes ZosterPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07361796 · 832 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 30, 2027
Drug: Venlafaxine combined conventional therapy; Conventional therapy · For: Herpes Zoster; Pain; Postherpetic Neuralgia
Sites: Beijing, China
- Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.Pivotal-lookingRecruiting
Labo'LifeIndustry
NCT04065971 · 140 participants (planned) · Start Mar 10, 2020 · Primary completion Mar 31, 2027
Drug: 2LHERP®; Placebo · For: Herpes Simplex
Sites: Beerzel, Belgium; Beuzet, Belgium; Bouge, Belgium · 6 sites in all
ImmVira Pharma Co. LtdIndustry
NCT06971614 · 160 participants (planned) · Start Jun 9, 2025 · Primary completion Dec 31, 2028
Drug: T3011 · For: Nonmuscle-invasive Bladder Cancer
Sites: Queen Creek, Arizona; Los Angeles, California; Orlando, Florida · 9 sites in all
ImmVira Pharma Co. LtdIndustry
NCT07243340 · 36 participants (planned) · Start Apr 3, 2026 · Primary completion Dec 15, 2027
Drug: Herpes Virus C5252 Injection · For: Glioma, Malignant
Sites: Tianjin, China
- Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BALPivotal-lookingRecruiting
Jena University HospitalAcademic, hospital or other
NCT06134492 · 616 participants (planned) · Start Feb 20, 2024 · Primary completion Jul 2026
Drug: Acyclovir · For: Pneumonia, Viral; Ventilator Associated Pneumonia; Community-acquired Pneumonia and 2 more
Sites: Freiburg im Breisgau, Germany; Heidelberg, Germany; Tübingen, Germany · 28 sites in all
- Subcutaneous Calcitonin in Acute Herpes ZosterPivotal-lookingRecruiting
Tanta UniversityAcademic, hospital or other
NCT07655804 · 168 participants (planned) · Start Jul 1, 2026 · Primary completion Apr 1, 2027
Drug: Calcitonin · For: Calcitonin; Subcutaneous; Acute Herpes Zoster
Sites: Tanta, Egypt
- Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker EvaluationPivotal-lookingRecruiting
Dexiong HanGovernment (non-federal)
NCT07515885 · 228 participants (planned) · Start Sep 1, 2025 · Primary completion Dec 31, 2028
Drug: Valacyclovir, pregabalin and mecobalamin · For: Acute Herpes Zoster
Sites: Hangzhou, China
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT07585370 · 24,740 participants (planned) · Start Mar 6, 2026 · Primary completion Jun 30, 2026
Drug: Attenuated Zoster Vaccine, Live; Matched Placebo Without Live Virus and 1 more · For: Herpes Zoster
Sites: Nanjing, China
- A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07502560 · 33,609 participants (planned) · Start Mar 31, 2026 · Primary completion Apr 1, 2030
Drug: Recombinant zoster vaccine; Placebo · For: Herpes Zoster
Sites: Espoo, Finland; Helsinki, Finland; Jarvenpaa, Finland · 8 sites in all
Yana NajjarAcademic, hospital or other
NCT06216938 · 25 participants (planned) · Start Mar 7, 2024 · Primary completion Mar 31, 2028
Drug: Vusolimogene oderparepvec (RP1) · For: Melanoma
Sites: Pittsburgh, Pennsylvania
- Shingrix in Renal Transplant RecipientsPivotal-lookingRecruiting
University of Colorado, DenverAcademic, hospital or other
NCT04128189 · 132 participants (planned) · Start Mar 2, 2023 · Primary completion Jun 2029
Drug: Shingrix · For: Kidney Transplant Recipient Response to Shingrix Vaccine; Kidney Failure; Kidney Failure, Chronic and 2 more
Sites: Aurora, Colorado; Atlanta, Georgia; Boston, Massachusetts · 4 sites in all
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes ZosterPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07307170 · 750 participants (planned) · Start Dec 15, 2025 · Primary completion Oct 31, 2027
Drug: Mirogabalin combined conventional therapy; Conventional therapy · For: Herpes Zoster; Mirogabalin; Pain
Sites: Beijing, China
University of Sao Paulo General HospitalAcademic, hospital or other
NCT07280741 · 200 participants (planned) · Start Dec 2, 2025 · Primary completion Jul 30, 2027
Drug: Recombinant Zoster Vaccine (RZV) · For: Autoimmune Rheumatic Diseases
Sites: São Paulo, Brazil
- A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney TransplantPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT04006808 · 184 participants (planned) · Start Oct 25, 2019 · Primary completion May 1, 2026
Drug: PED-HZ/su · For: Herpes Zoster
Sites: Brussels, Belgium; Ghent, Belgium; Leuven, Belgium · 31 sites in all
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA VaccinePivotal-lookingRecruiting
Sinovac Biotech Co., LtdIndustry
NCT07400003 · 519 participants (planned) · Start Jan 6, 2026 · Primary completion May 31, 2026
Drug: Low-dose experimental vaccine; High-dose experimental vaccine and 2 more · For: Herpes Zoster; mRNA Vaccine
Sites: Xinjiang, China
First People's Hospital of HangzhouAcademic, hospital or other
NCT06643247 · 8 participants (planned) · Start Nov 11, 2024 · Primary completion Dec 31, 2027
Drug: Drug · For: Herpes Zoster; Electroacupuncture; Immune
Sites: Hangzhou, China
- The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes ZosterPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07378046 · 750 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 30, 2027
Drug: Baclofen combined conventional therapy; Conventional therapy · For: Herpes Zoster; Pain
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.